GlassScriptPhysician profile
Muhammad Y Hamdan
NPI 1528091980
$1,810.87
in general payments reported to CMS, 2019-2025
31 companies · $72.27 in 2025
The $72.27 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $255 · 2021: $27.49 · 2022: $167 · 2023: $253 · 2024: $283 · 2025: $72.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580 · Education: $28.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.70 |
| Education | $28.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $243.43 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $198.00 | 2019 | |
| Celgene Corporation | $134.10 | 2023-2024 | Pomalyst, Reblozyl |
| Amgen INC. | $127.08 | 2019-2023 | |
| Janssen Biotech, INC. | $126.63 | 2019-2024 | Rybrevant |
| Pfizer INC. | $110.42 | 2019-2023 | |
| Abbvie INC. | $102.07 | 2022-2025 | |
| Daiichi Sankyo INC. | $73.75 | 2022-2024 | Vanflyta |
| Genentech USA, INC. | $72.83 | 2019-2022 | |
| Foundation Medicine, INC. | $62.31 | 2019-2020 | |
| Genzyme Corporation | $59.24 | 2019-2022 | |
| Gilead Sciences, INC. | $50.26 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.97 | 2019-2022 | |
| Lilly USA, LLC | $45.55 | 2019 | |
| Array Biopharma INC | $41.84 | 2020-2023 | Mektovi, Braftovi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.10 | 2019-2020 | |
| Astellas Pharma US INC | $37.64 | 2019-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $23.84 | 2023 | Enhertu |
| Servier Pharmaceuticals LLC | $21.77 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $19.37 | 2023 | Imbruvica |
| Emd Serono, INC. | $19.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.80 | 2019 | |
| Pharmaessentia USA Corporation | $18.45 | 2024 | Besremi |
| Agios Pharmaceuticals, INC. | $17.90 | 2019 | |
| Eisai INC. | $15.38 | 2020 | |
| Kite Pharma, INC. | $15.02 | 2019 | |
| Glaxosmithkline, LLC. | $14.75 | 2024 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $13.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.42 | 2019 | |
| Clovis Oncology, INC. | $12.90 | 2020 | |
| Puma Biotechnology, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Hamdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.